Loading
Adial Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 Jul 2026.
Adial Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Adial Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 15 filings came from 7 insiders.
No insider sold shares on the market over the period. Instead, the filings list 5 purchases totalling €36k, made by 1 insider. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 major shareholder. Coastlands Capital LP filed the largest purchase, €25k, on 13 July 2026, which represents 0.24% of the company's market value.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 15 filings here. The full history, which starts in 2021, counts 9 purchases against 1 sale.
The latest purchase dates back some time: it was published 93 days ago, on 16 July 2026. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
29
Thresholds
n/a
Buy Volume
€109,746
9 ops. · all time
Sell Volume
n/a
1 ops. · all time
Who traded when
BuySaleCoastlands Capital LP5 buys
Since the insiders bought
- +12.1%Entry US$2.80 · Close 15 Oct 2026 US$3.14
- -64.1%Entry US$67.50 · Close at T+365 US$24.25
- -90.5%Entry US$1,643.75 · Close at T+365 US$156.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.29
Analyst consensus
3 analysts1.75/5
US$6.00Target US$8.33(+153%)US$11.00
Income statement
EBITDA-US$7.8M
Net income-US$8M0.0% margin
Valuation
PER (forward)-0.4x
P/Book1.6x
Beta1.50
Balance sheet & cash
Market capUS$8.6M
Total debtUS$207.4k
Free Cash Flow-US$6.5M
Profitability & ownership
ROE-2011.6%
ROA-40.0%
% insiders7.1%
% institutions29.9%
Last declaration on 16 July 2026
Declarations29 total
1,233 shares@ US$2.750.028% mcap8.2% of flowCommon StockSEC:0001104659-26-084300:1
Canonical exit: 14 Oct 2026 (T+90)
2,000 shares@ US$2.650.045% mcap12.9% of flowCommon StockSEC:0001104659-26-084300:0
Canonical exit: 12 Oct 2026 (T+90)
10,053 shares@ US$2.790.24% mcap67.9% of flowCommon StockSEC:0001104659-26-082972:0
Canonical exit: 7 Oct 2026 (T+90)
1,700 shares@ US$2.700.038% mcap11.1% of flowCommon StockSEC:0001104659-26-082972:1
Canonical exit: 8 Oct 2026 (T+90)
25,000 sharesCommon StockSEC:0001104659-26-079686:0
Canonical exit: 27 Sept 2026 (T+90)
61,647 sharesCommon StockSEC:0001213900-26-069037:0
3,427 sharesCommon StockSEC:0001213900-26-069037:1
232,417 sharesCommon StockSEC:0001213900-26-069037:2
1,822.13 sharesSeries A Preferred StockSEC:0001213900-26-069037:3
101.298 sharesSeries A Preferred StockSEC:0001213900-26-069037:4
37,985 shares0Common StockSEC:0001213900-26-042050:0
17,325 shares0Common StockSEC:0001213900-26-042053:0
26,510 shares0Common StockSEC:0001213900-26-042054:0
9,185 shares0Common StockSEC:0001213900-26-042051:0
9,185 shares0Common StockSEC:0001213900-26-042052:0
700 shares@ US$2.74100.0% of flowCommon StockSEC:0001013762-23-000757:0
Canonical exit: 28 Dec 2023 (T+90)
240,800 shares0Common StockSEC:0001213900-23-043129:0
157,500 shares0Common StockSEC:0001213900-23-043133:0
420,000 shares0Common StockSEC:0001213900-23-043111:0
166,667 shares0Common StockSEC:0001213900-23-000003:0
25,000 shares@ US$0.429425.3% of flowCommon StockSEC:0001213900-22-057513:0
75,000 shares@ US$0.420274.7% of flowCommon StockSEC:0001213900-22-057513:1
1,000,000 shares0Common StockSEC:0001213900-22-050082:0
250,000 shares0Common StockSEC:0001213900-22-009432:0
10,000 shares@ US$2.6647.9% of flowCommon StockSEC:0001213900-22-000067:0
Canonical exit: 30 Mar 2022 (T+90)
25 of 29 declarations
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker ADIL in the United States. For French-speaking investors, it is best viewed as a development-stage healthcare name rather than a commercial-stage drug company. The business is headquartered in Glen Allen, Virginia, and its roots go back to ADial Pharmaceuticals, L.L.C., which was formed in November 2010 before later becoming a public corporation. Over time, Adial has built a focused clinical pipeline around addiction and related disorders.
The company’s core activity is the development of therapies for the treatment and prevention of alcohol use disorder and other addiction-related conditions. Its lead investigational asset is AD04, a serotonin-3 receptor antagonist being studied for Alcohol Use Disorder (AUD). Adial has positioned AD04 within a precision-medicine framework, emphasizing biomarker-based patient selection and a potentially differentiated approach to treatment. That matters strategically because the addiction-treatment market remains medically underserved, and successful drug development in this area could address a meaningful unmet need.
Read moreShow less
From a competitive standpoint, Adial sits in the small-cap biotech segment, where valuation is driven primarily by clinical milestones, regulatory progress, and access to capital. Its potential strengths include a narrow therapeutic focus and a lead asset aimed at a large and persistent public-health problem. However, the company also faces the usual biotech constraints: competition from larger pharmaceutical groups, uncertainty around clinical outcomes, and the need to secure financing before any meaningful product revenue can materialize. Until a product is approved and commercialized, Adial remains a high-risk, binary-outcome investment profile.
Geographically, the company’s operations are primarily U.S.-centered, and its corporate and regulatory footprint is firmly based in the United States. Recent company updates indicate that Adial has been advancing its FDA dialogue and preparing for a planned Phase 3 program for AD04, while also discussing potential partnering opportunities. A notable recent development came in February 2026, when the company announced that it had regained compliance with Nasdaq’s minimum bid-price requirement after earlier pressure on the share price and a reverse stock split. That episode underscores the company’s financing sensitivity and market volatility.
Overall, Adial Pharmaceuticals is a specialized NASDAQ-listed U.S. biotech company with a single lead program, a clear focus on addiction medicine, and a risk-return profile typical of clinical-stage pharmaceutical developers: significant upside tied to regulatory and clinical success, but substantial execution, funding, and dilution risk along the way.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
